Suppr超能文献

需要静脉通路装置的患者的抗血栓治疗和出血性疾病的管理:系统评价和 GAVeCeLT 共识声明。

Management of antithrombotic treatment and bleeding disorders in patients requiring venous access devices: A systematic review and a GAVeCeLT consensus statement.

机构信息

Vascular Access Team, University Hospital "A.Gemelli," Rome, Italy.

University of Genova and IRCCS "San Martino," Genova, Italy.

出版信息

J Vasc Access. 2022 Jul;23(4):660-671. doi: 10.1177/11297298211072407. Epub 2022 May 9.

Abstract

Insertion of venous access devices (VAD) is usually considered a procedure with low risk of bleeding. Nonetheless, insertion of some devices is invasive enough to be associated with bleeding, especially in patients with previous coagulopathy or in treatment with antithrombotic drugs for cardiovascular disease. The current practices of platelet/plasma transfusion in coagulopathic patients and of temporary suspension of the antithrombotic treatment before VAD insertion are based on local policies and are often inadequately supported by evidence, since many of the clinical studies on this topic are not recent and are not of high quality. Furthermore, the protocols of antithrombotic treatment have changed during the last decade, after the introduction of new oral anticoagulant drugs. Though some guidelines address some of these issues in relation with specific procedures (port insertion, etc.), no evidence-based document covering all the aspects of this clinical problem is currently available. Thus, the Italian Group of Venous Access Devices (GAVeCeLT) has decided to develop a consensus on the management of antithrombotic treatment and bleeding disorders in patients requiring VADs. After a systematic review of the available evidence, the panel of the consensus (which included vascular access specialists, surgeons, intensivists, anesthetists, cardiologists, vascular medicine experts, nephrologists, infective disease specialists, and thrombotic disease specialists) has structured the final recommendations as detailed answers to three sets of questions: (1) which is an appropriate classification of VAD-related procedures based on the specific bleeding risk? (2) Which is the appropriate management of the patient with bleeding disorders candidate to VAD insertion/removal? (3) Which is the appropriate management of the patient on antithrombotic treatment candidate to VAD insertion/removal? Only statements reaching a complete agreement were included in the final recommendations, and all recommendations were offered in a clear and synthetic list, so to be easily translated into clinical practice.

摘要

血管内装置(VAD)的插入通常被认为是一种出血风险较低的操作。然而,某些装置的插入具有足够的侵入性,可能与出血相关,尤其是在有先前凝血障碍或正在接受心血管疾病抗血栓治疗的患者中。目前,在有凝血障碍的患者中进行血小板/血浆输注以及在 VAD 插入前暂时停止抗血栓治疗的做法是基于当地政策的,并且通常没有得到充分的证据支持,因为许多关于这个主题的临床研究不是最近的,也不是高质量的。此外,在过去十年中,新型口服抗凝药物的出现改变了抗血栓治疗方案。尽管一些指南针对特定操作(如端口插入等)涉及到其中一些问题,但目前尚无涵盖这个临床问题所有方面的基于证据的文件。因此,意大利静脉通路装置小组(GAVeCeLT)决定就需要 VAD 的患者的抗血栓治疗和出血障碍管理达成共识。在对现有证据进行系统回顾后,共识小组(包括血管通路专家、外科医生、重症监护专家、麻醉师、心脏病专家、血管医学专家、肾病学家、传染病专家和血栓疾病专家)将最终建议组织为对三组问题的详细回答:(1)基于特定出血风险,VAD 相关操作的适当分类是什么?(2)有出血障碍且适合 VAD 插入/移除的患者应如何管理?(3)正在接受抗血栓治疗且适合 VAD 插入/移除的患者应如何管理?仅包括达成完全一致的陈述被纳入最终建议,并且所有建议都以清晰和综合的列表形式提供,以便于转化为临床实践。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验